1-[3-fluoro-4-(2-hydroxy-2-methylpropoxy)phenyl]-3-[4-(trifluoromethyl)phenylthio]pyrazine-2(1H)-one | 1099662-97-1

• 分子结构分类: 有机化合物 - 有机硫化合物 - 硫醚类
• 英文名称: 1-[3-fluoro-4-(2-hydroxy-2-methylpropoxy)phenyl]-3-[4-(trifluoromethyl)phenylthio]pyrazine-2(1H)-one
• 英文别名: 1-[3-Fluoro-4-(2-hydroxy-2-methylpropoxy)phenyl]-3-[4-(trifluoromethyl)phenyl]sulfanylpyrazin-2-one
• CAS: 1099662-97-1
• 化学式: C₂₁H₁₈F₄N₂O₃S
• 分子量: 454.445
• InChiKey: QIUDKYKLFYBAJA-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.4
• 重原子数：
  31
• 可旋转键数：
  6
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.24
• 拓扑面积：
  87.4
• 氢给体数：
  1
• 氢受体数：
  9

文献信息

• NON-BASIC MELANIN CONCENTRATING HORMONE RECEPTOR-1 ANTAGONISTS AND METHODS
  申请人：Stein Philip D.

  公开号：US20090011994A1

  公开（公告）日：2009-01-08

  The present application provides compounds, including all stereoisomers, solvates, prodrugs and pharmaceutically acceptable forms thereof according to Formula I wherein R 1 , R 2 , R 3 , R 8 , and R 9 are defined herein. Additionally, the present application provides pharmaceutical compositions containing at least one compound according to Formula I and optionally at least one additional therapeutic agent. Finally, the present application provides methods for treating a patient suffering from an MCHR-1 modulated disease or disorder such as, for example, obesity, diabetes, depression or anxiety by administration of a therapeutically effective dose of a compound according to Formula I.

  本申请提供了根据公式I提供的化合物，包括所有立体异构体、溶剂合物、前药和药学上可接受的形式， 其中 R 1 ，R 2 ，R 3 ，R 8 和R 9 在此定义。 此外，本申请提供了含有至少一种根据公式I的化合物和可选至少一种额外治疗剂的药物组合物。最后，本申请提供了治疗患有MCHR-1调节性疾病或紊乱的患者的方法，例如肥胖症、糖尿病、抑郁症或焦虑症，通过给予根据公式I的化��物的治疗有效剂量。
• SUBSTITUTED PYRAZINONE MELANIN CONCENTRATING HORMONE RECEPTOR-1 ANTAGONISTS AND METHODS
  申请人：Stein Philip D.

  公开号：US20110144060A1

  公开（公告）日：2011-06-16

  The present application provides compounds, including all stereoisomers, solvates, prodrugs and pharmaceutically acceptable forms thereof according to Formula I wherein R 1 , R 2 , R 3 , R 8 , and R 9 are defined herein. Additionally, the present application provides pharmaceutical compositions containing at least one compound according to Formula I and optionally at least one additional therapeutic agent. Finally, the present application provides methods for treating a patient suffering from an MCHR-1 modulated disease or disorder such as, for example, obesity, diabetes, depression or anxiety by administration of a therapeutically effective dose of a compound according to Formula I.

  本申请提供了一种化合物，包括所有立体异构体、溶剂化合物、前药和其制备的药学上可接受的形式，其化学式为I式，其中R1、R2、R3、R8和R9的定义如本文所述。此外，本申请还提供了含有至少一种I式化合物和可选的至少一种其他治疗剂的药物组合物。最后，本申请提供了通过给予I式化合物的治疗有效剂量来治疗患有MCHR-1调节性疾病或疾病的患者的方法，例如肥胖症、糖尿病、抑郁症或焦虑症。
• US8012984B2
  申请人：——

  公开号：US8012984B2

  公开（公告）日：2011-09-06
• US8067420B2
  申请人：——

  公开号：US8067420B2

  公开（公告）日：2011-11-29